Three-Year Follow-up of the Ascend Trial: Acalabrutinib Vs Rituximab Plus Idelalisib or Bendamustine in Relapsed/Refractory Chronic Lymphocytic Leukemia
暂无分享，去创建一个
J. H. Lee | Á. Illés | M. Šimkovič | P. Ghia | A. Pluta | S. Dolan | W. Jurczak | D. Lysák | T. Kozák | I. Kriachok | J. de la Serna | G. Musuraca | M. Wach | P. Campbell | E. Avery | M. Wang | A. Jacob | T. Yu